Additional Emerging HER2-Targeted Therapies in NSCLC
Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for non-small cell lung cancer.
Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC
Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.
Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLC
Explore the significance of patient-reported outcomes in cancer treatment, highlighting the benefits of zongertinib and its impact on quality of life.
Evaluating TKI Efficacy and Safety in HER2-Mutant NSCLC from SOHO-01 Trial
Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting its potential as a first-line treatment.
Efficacy and Safety of Zongertinib in Previously Treated and Treatment-Naïve HER2-Mutant NSCLC from Beamion LUNG-1 Trial
Discover the latest insights on Zongertinib's efficacy and safety for HER2-mutant non-small cell lung cancer, promising new treatment options.
Mechanistic Role of Emerging Tyrosine Kinase Inhibitors (TKIs) in HER2-Mutant NSCLC
Explore the differences between emerging HER2-targeted TKIs, Zongertinib and Seviberatinib, and their therapeutic implications in cancer treatment.
Overview of HER2-Targeted Therapies in NSCLC
Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.
Treatment of HER2-Mutant NSCLC: Consequences of Delays and Strategies to Improve Timely Initiation
Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for those with HER2 mutations.
Unmet Needs in HER2-Mutant NSCLC
Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and treatment access.
Value of Comprehensive Molecular Testing in NSCLC
Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.
Barriers to Adoption of SC Therapies
Panelists discuss how overcoming logistical and perceptual barriers will drive wider adoption of SC therapies in NSCLC.
Impact of SC Formulations on Pharmacy Operations
Panelists discuss how SC formulations streamline pharmacy workflows and optimize oncology practice efficiency.
Improving Adherence and Transitioning to SC Therapy
Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.
Counseling Patients on IV vs SC Administration
Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.
FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
The Value of Subcutaneous Therapy for Patients
Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
Sequencing Therapies and Using the Most Effective Options First
Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.
Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.
Subcutaneous Treatments Can Save Chair Time, Decrease Infusion Reaction in NSCLC: Joshua K. Sabari, MD
Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment.
Using AI to Individualize Clinical Pathways Is the Future of Precision Oncology: Joshua K. Sabari, MD
Using artificial intelligence (AI) to specialize treatment for patients with different kinds of cancer can be a boon to clinicians looking to personalize their care.
Clinicians Should Look Beyond NGS When Delivering Precision Oncology: Joshua K. Sabari, MD
New methods of testing tissue and plasma beyond next-generation sequencing (NGS) could be used to deliver the best therapeutic options for patients with cancer.
CNS Penetration and Efficacy of Emerging Therapies
Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.
Impact of Recent Approvals and Novel Mechanisms
Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.
Overcoming Resistance Mechanisms and Addressing Unmet Needs
Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.
Understanding EGFR Mutations and First-Line Treatment
Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.
